folic acid has been researched along with Precursor T-Cell Lymphoblastic Leukemia-Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexe, G; Conway, AS; Diehl, FF; Dimitrov, B; Kitara, S; Lewis, CA; Ling, F; Ocasio-Martinez, N; Pikman, Y; Puissant, A; Qi, J; Robichaud, AL; Ross, L; Roti, G; Stegmaier, K; Su, A; Vander Heiden, MG | 1 |
| Bradner, JE; Ferrando, AA; Kitara, S; Kung, AL; Qi, J; Roti, G; Sanchez-Martin, M; Saur Conway, A; Stegmaier, K; Su, A; Varca, AC; Wu, L | 1 |
2 other study(ies) available for folic acid and Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Proliferation; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Folic Acid; Glycine Hydroxymethyltransferase; Humans; Methotrexate; Mice; Mice, Inbred NOD; Mice, SCID; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2022 |
Leukemia-specific delivery of mutant NOTCH1 targeted therapy.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Endocytosis; Folate Receptor 2; Folic Acid; Gene Expression; Humans; Leukemia; Mice; Mutation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Receptor, Notch1; Signal Transduction; Thapsigargin; Xenograft Model Antitumor Assays | 2018 |